The role of the microbiome in NAFLD and NASH
Open accessThe DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro‐inflammatory and anti‐inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota‐derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of these TLRs can contribute to the development of NAFLD and nonalcoholic steatohepatitis (NASH), with the most extensively studied pathway being LPS-TLR4 signaling.180”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 2×
“However, conven-tionalization of germ-free mice with normal mouse microbiota induces de novo hepatic lipogenesis, in addition to increased body fat content and insulin resistance (Ba¨ckhed et al , 2004).”
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Intestinal mucosal barrier function in health and disease
Turner, J. R. (2009) · Nature reviews. Immunology · doi:10.1038/nri2653 · Cited by 3,952 · cited 1×
“Under physiological conditions, tight junction proteins, such as zonula occludens, seal adjacent epithelial cells at the apical sites and prevent bacteria from entering the intestinal mucosa and the bloodstream (Turner, 2009).”
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“…in the digestion of food and facilitates the absorption of the dietary molecules into the portal and systemic circulation (Jumpertz et al , 2011; Ridaura et al , 2013), interacts with the mucosal immune system, to shape development of its antigen recognition, recruitment, proliferation, and…”
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 3×
“In addition, SCFAs are also potent signaling molecules through binding to G-protein-coupled receptors GPR41, GPR43, and GPR109A (Samuel et al , 2008; Maslowski et al , 2009).”
Research works printed but not linked: 1
- Ackermann D, Schutze H (1910) The formation of trimethylamine by bacterium prodigiosum. Zentralb Physiol 24: 210–211
Cited by
Items 501–548 of 548
Impact de perturbateurs endocriniens sur la stéatose hépatique et sa progression pathologique
Mentec, H. L. (2023) · theses.fr (ABES) · doi:10.70675/ecaf4c85z1295z4280zb43ezdb58695f5ff8
Beier, J. I., Medici, V., Spencer, S. P., Fan, W., & Torok, N. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00006-6
Chen, L., Lei, Y., Lu, H., & Wang, Y. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250208
Manteghian, M. (2024) · University of Toronto Medical Journal · doi:10.33137/utmj.v101i2.41857
The Modulation of Gut Microbiota by Bariatric Metabolic Surgery and Its Role in NAFLD Treatment
郝, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482288
Fatty liver disease: An updated overview of risk factors
Alsayegh, A. S., Alduaybi, M. A., Alanizi, H. G., Alajmi, N. A. A., Saeed, S. M. B., Owias, M. I. Z. A., Rashedi, A. A. A., Alqahtani, A. S., & Alanezi, B. S. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v7ns1.15308
The Role of the Intestinal Microbiota in NAFLD Onset and Progression
Pinheiro, I. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1007741
Mikrobiom und MASLD, Leberzirrhose und Leberkarzinom
Stadlbauer, V. (2024) · Springer eBooks · doi:10.1007/978-3-662-68455-9_11
Sirchak, Y. S. (2025) · ScienceRise Medical Science · doi:10.15587/2519-4798.2025.329828
Li, S., Jin, C., & Duan, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6871240/v1
Research Progress on the Therapeutic Effect of Lychee Seed Extract on Non-Alcoholic Steatohepatitis
司, 砚. (2025) · Asian Case Reports in Emergency Medicine · doi:10.12677/acrem.2025.133041
Suzuki, K. T., Nagasaki, A., Sakamoto, S., Ouhara, K., Hyogo, H., Aikata, H., Takemoto, T., Tanaka, A., Funakoshi, G., Koyama, Y., et al. (2025) · medRxiv · doi:10.1101/2025.09.01.25334816
Seeger, A., Babbar, A., Eswaran, S., Adams, M., Muschaweck, M., Treichel, N. S., Clavel, T., Yin, G., Guillot, A., Scheuer, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.678237
Bahitham, W., Banoun, Y., Aljahdali, M., Aljahdali, L., Sanai, F. M., Sergi, C. M., & Rosado, A. S. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012215
Microbiota en la Infancia Temprana y su Impacto Inmunológico: Un Enfoque Multidisciplinario
de Tamaulipas, U. A., Escobedo, R. D. L., Pérez, B. G., de Tamaulipas, U. A., Flores, R. S., de Tamaulipas, U. A., Cárdenas, J. E. G., & de Tamaulipas, U. A. (2025) · doi:10.29059/luat.434
Gulden, L., & Stadlbauer, V. (2025) · Springer eBooks · doi:10.1007/978-3-662-70167-6_4
Johira, Y., Nakahara, T., Kinami, T., Yamasaki, S., Kosaka, M., Shirane, Y., Miura, R., Murakami, S., Yano, S., Amioka, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600491
Deciphering the role of the gut microbiota in murine MASH and MASH-to-HCC transition
Schühle, S. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00034638
Lange, E. C. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Beskow, C. B. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Construction and Evaluation of a Mouse Model of Nonalcoholic Steatohepatitis in C57BL/6 Mice
高, 丽. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123408
Current Research Status on the Pathogenesis of Metabolic Dysfunction-Associated Fatty Liver Disease
张, 月. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123656
Chen, J., Yu, X., Nian, F., Si, J., Chen, Y., Zhou, D., Zhang, G., & Dong, L. (2026) · Liver International · doi:10.1111/liv.70527
Analysis of biomarkers in the Human Phenotype Project using disease models from UK Biobank
Pellow, D., Geva, G. A., Godneva, A., Reisner, Y., Talmor‐Barkan, Y., & Segal, E. (2026) · Med · doi:10.1016/j.medj.2025.100993
Nutritional Epidemiology: Advances in the Analysis of Healthy and Sustainable Dietary Patterns
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7564-2
Характеристика літичних бактеріофагів Proteus mirabilis
Седоченко, Є. О. (2024) · eKNUTSHIR
Implications du microbiote intestinal et de la pectine dans la stéato-hépatite non-alcoolique
Houron, C. (2020) · theses.fr (ABES) · doi:10.70675/282e9d85z4f3dz4f5bz9045zd1ce6da72037
Morisseau, L. (2023) · theses.fr (ABES) · doi:10.70675/cfa5953ez697dz47bez9768zde0845d5a7b8 · Cited by 1
Wang, S., Hullar, M. A. J., Curtis, K. R., Kwee, S. A., Park, S., Rettenmeier, C. A., Monroe, K. R., Ernst, T. M., Shepard, J., Wilkens, L. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.10.717245
Ruan, S., Liu, S., Zhang, X., Zhang, J. Y., Chen, C., Lu, H., Zheng, K., Fang, S., & Chen, X. (2026) · Medicine · doi:10.1097/md.0000000000048269
Meng, Q., Zhang, H., Ye, J., Liu, T., Li, Y., Song, W., Luo, Y., & Yue, T. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-026-01020-9
Huang, B., Tian, C., & Sui, Y. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.42
From cooperation to collapse: the diet-microbiota-host gene triad in disease and aging
Bhattacharjee, S., & Mukhopadhyay, A. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2026.1872481
Swierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
Geometry‐Mediated Microgel Structure‐Mechanics for Intestinal Region‐Specific Probiotic Delivery
Chen, S., Shang, W., Wang, Q., Landman, J., Livney, Y. D., Zhang, Y., Thum, C., Chen, S., Zhai, Z., Liu, X., et al. (2026) · Advanced Materials · doi:10.1002/adma.75011
Shang, J., Yang, F., Chen, H., & Cui, H. (2026) · Dyes and Pigments · doi:10.1016/j.dyepig.2026.114243
Gut microbiota shaping fatty liver disease progression
Wysokińska, M., Mysza, M., Uryga, A., & Kolodziejczyk, A. A. (2026) · Life Science Alliance · doi:10.26508/lsa.202603756
Self-citationLi, S., Sheng, W., Yang, Y., Li, P., Su, Q., Shi, Z., Zhou, J., Yuan, H., & Feng, S. (2026) · Microorganisms · doi:10.3390/microorganisms14102315
Ros‐Madrid, I., Martínez‐Sánchez, M. A., Cano-Mármol, R. P., Rico‐Chazarra, S., Sánchez‐Alcoholado, L., Fernández-Ruiz, V. E., González-González, A., Martínez, C. M., Silva, A., Gurzov, E. N., et al. (2026) · Nutrients · doi:10.3390/nu18213548
Trabelsi, K., Ammar, A., Boujelbane, M. A., Puce, L., Garbarino, S., Scoditti, E., Boukhris, O., Khanfir, S., Clark, C. C. T., Glenn, J. M., et al. (2022) · doi:10.3389/fnut.2022.1036496.s001
He, Z., Li, X., Yang, H., Wu, P., Wang, S., Cao, D., Guo, X., Xu, Z., Gao, J., Zhang, W., et al. (2021) · doi:10.3389/fnut.2021.745609.s001
Simas, A. M., Kramer, C. D., & Genco, C. A. (2022) · doi:10.3389/froh.2021.784448.s001
Lv, S., Zhang, Z., Su, X., Li, W., Wang, X., Pan, B., Li, H., Zhang, H., & Wang, Y. (2023) · doi:10.3389/fendo.2022.1106875.s001
Shen, B., Wang, J., Guo, Y., Gu, T., Shen, Z., Zhou, C., Li, B., Xu, X., Li, F., Zhang, Q., et al. (2021) · doi:10.3389/fmicb.2021.756299.s005
Metadata
- Authors
- Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E.
- Affiliations
- Weizmann Institute of Science (IL)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Tel Aviv Sourasky Medical Center (IL)
- Corresponding author
- Elinav, Eran
- Venue
- EMBO Molecular Medicine
- Published
- 2018-12-27
- Volume
- 11
- Issue
- 2
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6365925
- OpenAlex
- W2907493655
- Cited by
- 523
- References
- 125
- Citations by year
- 2026: 30 · 2025: 63 · 2024: 73 · 2023: 94 · 2022: 91 · 2021: 76 · 2020: 71 · 2019: 25
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Union's Horizon 2020 (747114)
- European Crohn's and Colitis Organization (ECCO) Fellowship
- Ke Lin Program of the First Affiliated Hospital of Sun Yat‐sen University
- Alexander Grass foundation
- Y. and R. Ungar
- Gurwin Family Fund for Scientific Research
- Crown Endowment Fund for Immunological Research
- Else Kroener‐Fresenius Foundation
- Benoziyo Endowment Fund for the Advancement of Science
- Adelis Foundation
- French National Center for Scientific Research
- European Research Council
- Marie Curie Integration grant
- Rising Tide Foundation
- Helmholtz Foundation
- Canadian Institute of Advanced Research
- The Bill & Melinda Gates Foundation & Howard Hughes Medical Institute
- Abisch‐Frenkel Foundation for the Promotion of Life Sciences
- Leona M. and Harry B. Helmsley Charitable Trust
- German–Israeli Foundation for Scientific Research and Development
- Israel Science Foundation
- Minerva Foundation
- European Foundation for the Study of Diabetes
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, microbiome, cardiometabolic syndrome, obesity, diabetes mellitus, dyslipidemia, hepatic lipid metabolism, hepatic carbohydrate metabolism, inflammation, gut microbiota metabolites, liver cirrhosis, hepatocellular carcinoma
- MeSH terms
- Gastrointestinal Microbiome, Bacteria, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Disease Progression, Carbohydrate Metabolism, Lipid Metabolism, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.